Journal Information
Vol. 46. Issue 6.
Pages 310-316 (June 2010)
Share
Share
Download PDF
More article options
Vol. 46. Issue 6.
Pages 310-316 (June 2010)
Original Article
Full text access
Antibiotic therapy and Effects of Respiratory Physiotherapy Techniques Cystic Fibrosis Patients Treated for Acute Lung Exacerbation: an Experimental Study
Efectos de la antibioterapia y la técnica fisioterápica respiratoria en pacientes con fibrosis quística tratados por exacerbación pulmonar aguda: estudio experimental
Visits
5257
Camila Isabel da Silva Santosa,
Corresponding author
, Maria Angela Gonçalves de Oliveira Ribeirob, André Moreno Morcilloc, Antônio Fernando Ribeiroc, José Dirceu Ribeiroc
a Paediatric Physiotherapy Service of Faculty of Medical Sciences, University of Campinas (UNICAMP) de São Paulo (SP), State University of Santa Catarina (UDESC) (SC), Brazil
b Paediatric Physiotherapy Service, Center for Pediatric Research (CIPED) of Faculty of Medical Sciences, University of Campinas (UNICAMP) de São Paulo (SP), State University of Santa Catarina (UDESC) (SC), Brazil
c Department of Pediatrics/CIPED of Faculty of Medical Sciences, University of Campinas (UNICAMP) de São Paulo (SP), State University of Santa Catarina (UDESC) (SC), Brazil
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics
Abstract
Introduction

Intravenous antibiotics in combination with intensive respiratory physiotherapy were evaluated for acute lung exacerbations in chronic infections of Pseudomonas aeruginosa in cystic fibrosis patients. Forced expiratory technique (FET) was assessed during hospital stay and discharge. The aim of this study was 1) to evaluate the immediate effects of FET and of 2) Intravenous antibiotics in combination with daily respiratory physiotherapy (IA+RPT) on parameters of lung function, body anthropometry and clinical scores of cystic fibrosis patients with acute lung exacerbation with chronic infection by Pseudomonas aeruginosa, during hospital stay and at hospital discharge after clearing the infection.

Patients and method

Eighteen patients between 7–28 years old were included in a prospective non-controlled clinical study. Body anthropometry values, Cystic Fibrosis Clinical Score (CFCS) exacerbation, Cystic Fibrosis Foundation Score (CFFS), and severity scores (SS) were evaluated before and after admission. Oxygen saturation (SpO2), heart (HR) and respiratory rate (RR) were evaluated before and after FET.

Results

CFCS (32.4+7.2) and CFFS (6.4+1.7) had decreased at hospital discharge for 18.9+3.3 and 0.3+0.5, respectively (p < 0.001). IA+ RPT reduced RR means (p = 0.003) and increased SpO2 (p = 0.006), forced expiration volume at 1 min (FEV1) (p = 0.021) and nutritional values (p = 0.002). During admission, FET immediately improved HR (p = 0.028), RR (p = 0.001) and SpO2 (p = 0.015), despite significant maximum voluntary ventilation reduction (p = 0.028); after the infection was treated the FET did not significantly alter parameters.

Conclusion

IA+RPT improved clinical conditions of cystic fibrosis patients. FET improved cardiorespiratory variables of patients at risk for infection.

Keywords:
Cystic fibrosis
Paediatric
Chest physiotherapy
Pseudomonas aeruginosa
Resumen
Introducción

Se evaluó el tratamiento con antibióticos intravenosos en combinación con la fisioterapia respiratoria intensiva para las exacerbaciones pulmonares agudas de las infecciones crónicas por Pseudomonas aeruginosa en pacientes con fibrosis quística. Durante la hospitalización y el alta se evaluó la técnica de espiración forzada (TEF). El objetivo de este estudio fue 1) valorar los efectos inmediatos de la TEF y de 2) los antibióticos intravenosos combinados con la fisioterapia respiratoria diaria (AI+FTR) sobre los parámetros de función pulmonar, antropometría corporal y puntuaciones clínicas de pacientes con fibrosis quística y exacerbaciones pulmonares agudas de una infección crónica por Pseudomonas aeruginosa en la hospitalización y el momento del alta hospitalaria tras remisión de la infección.

Pacientes y métodos

En un estudio clínico prospectivo, no controlado, se incluyeron 18 pacientes, de 7-28 años de edad. Antes y después de la hospitalización se evaluaron los valores antropométricos corporales, exacerbación de la puntuación Cystic Fibrosis Clinical Score, Cystic Fibrosis Foundation Score y puntuaciones de gravedad (PG). Antes y después de la TEF, se evaluaron la saturación de oxígeno (SpO2), FC y FR.

Resultados

En el momento del alta hospitalaria, la Cystic Fibrosis Clinical Score (32,4 + 7,2) y Cystic Fibrosis Foundation Score (6,4 + 1,7) habían disminuido 18,9 + 3,3 y 0,3 + 0,5, respectivamente (p < 0,001). La AI+FTR redujo la FR media (p = 0,003) y aumentó la SpO2 (p = 0,006), el volumen espiratorio forzado en el primer segundo (p = 0,021) y los valores nutricionales (p = 0,002). En el momento de la hospitalización, la TEF mejoró de inmediato la FC (p = 0,028), FR (p = 0,001) y la SpO2 (p = 0,015), a pesar de un reducción significativa de la ventilación voluntaria máxima (p = 0,028); tras la remisión de la infección, la TEF no alteró significativamente los parámetros.

Conclusión

La AI+FTR mejoró el estado clínico de los pacientes con fibrosis quística. La TEF mejoró las variables cardiorrespiratorias de los pacientes con riesgo de infección.

Palabras clave:
Fibrosis quística
Pediátrico
Fisioterapia torácica
Pseudomonas aeruginosa
Full text is only aviable in PDF
References
[1.]
S.A. Prasad, E. Main, M.E. Dodd.
Finding consensus on the physiotherapy management of assymptomatic infants with Cystic Fibrosis.
Pediatr Pulmonol, 43 (2008), pp. 236-244
[2.]
G. Döring, S.P. Cönway, H.G.M. Heiherman, M.E. Hodson, N. Noiby, A. Smyth, et al.
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus.
Eur Respir J, 16 (2000), pp. 749-767
[3.]
A.E. Alvarez, A.F. Ribeiro, G. Hessel, C.S. Bertuzzo, J.D. Ribeiro.
Cystic fibrosis at a Brazilian center of excellence: clinical and laboratory characteristics of 104 patients and their association with genotype and disease severity.
J Pediatr, 80 (2004), pp. 371-379
[4.]
A. Smyth, J.S. Elborn.
Exacerbations in cystic fibrosis: management.
Thorax, 63 (2008), pp. 180-184
[5.]
D.G. Downey, S. Brockbank, S.L. Marptin, M. Ennis, J.S. Elborn.
The effect of treatment of cystic fibrosis pulmonary exacerbations on airway and systemic inflamation.
Pediatr Pulmonol, 42 (2007), pp. 729-735
[6.]
L. Béghin, F. Gottrand, L. Michaud, G.A. Loueville, N. Wizla-Derambure, A. Sardet, et al.
Impact of intravenous antibiotic therapy on total daily energy expenditure and physical activity in cystic fibrosis children with Pseudomonas aeruginosa pulmonary exacerbation.
[7.]
J. Bradley, O. McAlister, S. Elborn.
Pulmonar function, inflammation, exercise capacity and quality of life in cystic fibrosis.
Eur Respir J, 17 (2001), pp. 712-715
[8.]
M. Vendrell, J. Gracia, C. Olveira, M.A. Martínez, R. Girón, L. Máiz, et al.
Diagnosis and treatment of bronchiectasis.
Arch Bronconeumol, 44 (2008), pp. 629-640
[9.]
M. Mcllwaine.
Chest physical therapy, breathing techniques and exercise in children with cystic fibrosis.
Paediatr Respir Rev, 8 (2007), pp. 8-16
[10.]
J.M. Bradley, F.M. Moran, J.S. Elborn.
Evidence for physical therapies (airway clearance and physical training) in cystic fibrosis: An overview of five Cochrane systematic reviews.
Respir Med, 100 (2006), pp. 191-201
[11.]
Clinical Guidelines for the Physiotherapy Management of Cystic Fibrosis. Cftrust.org [homepage on the Internet]. UK: Association of Chartered Physiotherapist in Cystic Fibrosis. (ACPCF); [updated 2002 January 16; cited 2002 Jul 9]. Avaliable from: www.cftrust.org.uk.
[12.]
D.R. Hess.
The evidence for secretion clearance techniques.
Respir Care, 46 (2001), pp. 1276-1292
[13.]
G.M. Hafen, S.C. Ranganathan, C.F. Roberptson, P.J. Robinson.
Clinical Scoring System in Cystic Fibrosis.
Pediatr Pulmonol, 41 (2006), pp. 602-617
[14.]
C.I.S. Santos, J.D. Ribeiro, A.F. Ribeiro, G. Hessel.
Critical analise for cystic fibrosis clinical scores: state of art.
J Bras Pneumol, 30 (2004), pp. 286-298
[15.]
T.J. Newton.
Respiratory care of the hospitalized patient with cystic fibrosis.
Respir Care, 54 (2009), pp. 769-775
[16.]
J. Kanga, R. Kuhn, L. Craigmyle, D. Haverstock, D. Church.
Cystic Fibrosis Clinical Score: a new scoring system to evaluate acute pulmonary exacerbation.
Clin Ther, 21 (1999), pp. 1343-1356
[17.]
B.W. Ramsey, T.F. Boat.
Outcome measures for clinical trials in Cystic Fibrosis. Summary of a Cystic fibrosis Foundation Consensus Conference.
J Pediatr, 124 (1994), pp. 177-192
[18.]
American Thoracic Society.
Standardization of spirometry, 1994 update.
Am J Respir Crit Care Med, 152 (1995), pp. 1107-1136
[19.]
D. Homnick.
Making airway clearance successful.
Paediatric Respir Rev, 8 (2007), pp. 40-45
[20.]
M.T. Williams, D.W. Parson, R.A. Frick, E.R. Ellis, A.J. Martin, S.E. Giles, et al.
Acute respiratory infection in patients with cystic fibrosis with mild pulmonary impairment: comparison of two physiotherapy regimens.
Aust J Physiother, 47 (2001), pp. 227-236
[21.]
C.L. Ren, J.L. Brucker, A.K. Rovitelli, K.A. Bordeaux.
Changes in lung function measured by spirometry and the forced oscillation technique in cystic fibrosis patients undergoing treatment for respiratory tract exacerbation.
Pediatr Pulmonol, 41 (2006), pp. 345-349
[22.]
C. Braggion, L.M. Cappelletti, M. Cornacchia, L. Zanolla, G. Mastella.
Short-term effects of three chest physiotherapy regimens in patients hospitalized for pulmonary exacerbation of cystic fibrosis: a cross-over randomized study.
Pediatr Pulmonol, 19 (1995), pp. 16-22
[23.]
D.G. Brosworpth, D.W. Nielson.
Effectiveness of home versus hospital care in the routine treatment of cystic fibrosis.
Pediatr Pulmonol, 24 (1997), pp. 42-47
[24.]
B. Oberwaldner, B. Theissi, A. Rucker, M.S. Zach.
Chest physiotherapy in hospitalized patients with cystic fibrosis: a study of lung function effects and sputum production.
Eur Respir J, 4 (1991), pp. 152-158
[25.]
D.R. Hess.
Airway clearance: physiology, pharmacology, techniques and practice.
Respir Care, 52 (2007), pp. 1392-1396
[26.]
J.R. Rodrigues, C.AC. Pereira.
Spirometric response to bronchodilators: which parameters and values are clinically relevant in obstructive diseases?.
J Pneumol, 27 (2001), pp. 35-47
[27.]
L. Dorlochter, R. Ola, V. Helgheim, K. Rosendahl, G. Fluge.
Resting energy expenditure and lung disease in cystic fibrosis.
J Cyst Fibros, 1 (2002), pp. 131-136
[28.]
M. Castro, A. Diamanti, M. Gambarra, S. Bella, V. Lucidi, B. Papadatou, et al.
Resting energy expenditure in young patients with cystic fibrosis receiving antibiotic therapy for acute respiratory exacerbations.
Clin Nutr, 21 (2002), pp. 141-144
[29.]
C.P. Van der Shans.
Bronchial mucus transport.
Respir Care, 52 (2007), pp. 1150-1156
[30.]
M.S. Zach.
The physiology of forced expiration.
Paediatr Respir Rev, 1 (2000), pp. 3-39
Copyright © 2010. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?